Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Determining what age to move from stocks to bonds is vital for long-term financial health. Explore guidelines to help you plan your investment strategy.
23,118 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
What if a smart, data-backed ETF choice could help you finish 2026 with solid returns from the S&P 500? This guide br...
Lucid shares rebound for a second day after the CEO refutes bankruptcy and take-private rumors, with investors eyeing...
Policy experts say what trump's generic drug tariffs could mean for prices and supplies is uncertain, with effects de...
Microsoft stock pulled back early in 2026, turning headlines into a real question for investors: down 15%, should mic...
As AMC gears up for earnings, investors are asking if the meme-stock buzz can turn into real profits. This article br...
A new cross-asset note from Morgan Stanley says AI will reshape jobs rather than wipe them out, pushing workers towar...
Markets can overreact to short-term costs even when the long-term AI story is intact. This article outlines one overs...
FMC Corporation has faced headwinds that can derail even strong portfolios. Here are two words that should make inves...
A volatile March sell-off reshaped sentiment around Western Digital and Seagate. Western Digital’s move to fortify it...
What if the Oracle of Omaha retired having not purchased his beloved stock after decades of bets? This article dives ...
TD Cowen signals Congress is edging toward a permanent ban on a Federal Reserve CBDC, a move that could reshape the c...